Seek Returns logo

ALHC vs. NBIX: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ALHC and NBIX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

NBIX’s market capitalization of 12.78 billion USD is significantly greater than ALHC’s 2.68 billion USD, highlighting its more substantial market valuation.

ALHC’s beta of 1.22 points to significantly higher volatility compared to NBIX (beta: 0.24), suggesting ALHC has greater potential for both gains and losses relative to market movements.

SymbolALHCNBIX
Company NameAlignment Healthcare, Inc.Neurocrine Biosciences, Inc.
CountryUSUS
SectorHealthcareHealthcare
IndustryMedical - Healthcare PlansDrug Manufacturers - Specialty & Generic
CEOJohn E. KaoKyle W. Gano
Price13.57 USD129.11 USD
Market Cap2.68 billion USD12.78 billion USD
Beta1.220.24
ExchangeNASDAQNASDAQ
IPO DateMarch 26, 2021May 23, 1996
ADRNoNo

Historical Performance

This chart compares the performance of ALHC and NBIX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ALHC vs. NBIX: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ALHC

-81.24%

Medical - Healthcare Plans Industry

Max
13.94%
Q3
13.62%
Median
11.42%
Q1
7.74%
Min
6.98%

ALHC has a negative Return on Equity of -81.24%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

NBIX

11.81%

Drug Manufacturers - Specialty & Generic Industry

Max
51.32%
Q3
9.89%
Median
-3.37%
Q1
-20.99%
Min
-36.07%

In the upper quartile for the Drug Manufacturers - Specialty & Generic industry, NBIX’s Return on Equity of 11.81% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ALHC vs. NBIX: A comparison of their ROE against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Return on Invested Capital

ALHC

-15.02%

Medical - Healthcare Plans Industry

Max
15.50%
Q3
7.12%
Median
5.48%
Q1
-3.47%
Min
-15.02%

ALHC has a negative Return on Invested Capital of -15.02%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

NBIX

10.31%

Drug Manufacturers - Specialty & Generic Industry

Max
22.54%
Q3
8.45%
Median
1.42%
Q1
-9.01%
Min
-28.41%

In the upper quartile for the Drug Manufacturers - Specialty & Generic industry, NBIX’s Return on Invested Capital of 10.31% signifies a highly effective use of its capital to generate profits when compared to its peers.

ALHC vs. NBIX: A comparison of their ROIC against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Net Profit Margin

ALHC

-3.02%

Medical - Healthcare Plans Industry

Max
3.23%
Q3
2.62%
Median
1.70%
Q1
1.27%
Min
1.22%

ALHC has a negative Net Profit Margin of -3.02%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

NBIX

12.68%

Drug Manufacturers - Specialty & Generic Industry

Max
40.33%
Q3
11.92%
Median
-0.45%
Q1
-13.07%
Min
-34.27%

A Net Profit Margin of 12.68% places NBIX in the upper quartile for the Drug Manufacturers - Specialty & Generic industry, signifying strong profitability and more effective cost management than most of its peers.

ALHC vs. NBIX: A comparison of their Net Profit Margin against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Operating Profit Margin

ALHC

-2.19%

Medical - Healthcare Plans Industry

Max
4.30%
Q3
3.77%
Median
2.61%
Q1
1.60%
Min
-1.64%

ALHC has a negative Operating Profit Margin of -2.19%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

NBIX

20.61%

Drug Manufacturers - Specialty & Generic Industry

Max
46.91%
Q3
19.02%
Median
6.23%
Q1
-11.23%
Min
-51.89%

An Operating Profit Margin of 20.61% places NBIX in the upper quartile for the Drug Manufacturers - Specialty & Generic industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

ALHC vs. NBIX: A comparison of their Operating Margin against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Profitability at a Glance

SymbolALHCNBIX
Return on Equity (TTM)-81.24%11.81%
Return on Assets (TTM)-10.12%8.29%
Return on Invested Capital (TTM)-15.02%10.31%
Net Profit Margin (TTM)-3.02%12.68%
Operating Profit Margin (TTM)-2.19%20.61%
Gross Profit Margin (TTM)11.57%98.25%

Financial Strength

Current Ratio

ALHC

1.69

Medical - Healthcare Plans Industry

Max
1.91
Q3
1.63
Median
1.43
Q1
0.85
Min
0.78

ALHC’s Current Ratio of 1.69 is in the upper quartile for the Medical - Healthcare Plans industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

NBIX

3.13

Drug Manufacturers - Specialty & Generic Industry

Max
5.74
Q3
3.37
Median
2.64
Q1
1.73
Min
0.88

NBIX’s Current Ratio of 3.13 aligns with the median group of the Drug Manufacturers - Specialty & Generic industry, indicating that its short-term liquidity is in line with its sector peers.

ALHC vs. NBIX: A comparison of their Current Ratio against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Debt-to-Equity Ratio

ALHC

0.07

Medical - Healthcare Plans Industry

Max
1.06
Q3
0.86
Median
0.75
Q1
0.66
Min
0.66

At 0.07, ALHC’s Debt-to-Equity Ratio is unusually low for the Medical - Healthcare Plans industry. This highlights a conservative capital structure, suggesting the company prioritizes financial stability over aggressive growth funded by debt.

NBIX

0.18

Drug Manufacturers - Specialty & Generic Industry

Max
1.45
Q3
1.06
Median
0.62
Q1
0.13
Min
0.00

NBIX’s Debt-to-Equity Ratio of 0.18 is typical for the Drug Manufacturers - Specialty & Generic industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ALHC vs. NBIX: A comparison of their D/E Ratio against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Interest Coverage Ratio

ALHC

-2.98

Medical - Healthcare Plans Industry

Max
6.23
Q3
6.23
Median
5.19
Q1
4.64
Min
3.18

ALHC has a negative Interest Coverage Ratio of -2.98. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

NBIX

--

Drug Manufacturers - Specialty & Generic Industry

Max
10.17
Q3
3.39
Median
0.85
Q1
-2.63
Min
-5.84

Interest Coverage Ratio data for NBIX is currently unavailable.

ALHC vs. NBIX: A comparison of their Interest Coverage against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Financial Strength at a Glance

SymbolALHCNBIX
Current Ratio (TTM)1.693.13
Quick Ratio (TTM)1.693.02
Debt-to-Equity Ratio (TTM)0.070.18
Debt-to-Asset Ratio (TTM)0.010.12
Net Debt-to-EBITDA Ratio (TTM)10.900.47
Interest Coverage Ratio (TTM)-2.98--

Growth

The following charts compare key year-over-year (YoY) growth metrics for ALHC and NBIX. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ALHC vs. NBIX: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ALHC vs. NBIX: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ALHC vs. NBIX: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ALHC

0.00%

Medical - Healthcare Plans Industry

Max
3.88%
Q3
1.78%
Median
0.73%
Q1
0.00%
Min
0.00%

ALHC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

NBIX

0.00%

Drug Manufacturers - Specialty & Generic Industry

Max
9.29%
Q3
0.31%
Median
0.00%
Q1
0.00%
Min
0.00%

NBIX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ALHC vs. NBIX: A comparison of their Dividend Yield against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Dividend Payout Ratio

ALHC

0.00%

Medical - Healthcare Plans Industry

Max
63.88%
Q3
29.91%
Median
12.57%
Q1
0.00%
Min
0.00%

ALHC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

NBIX

0.00%

Drug Manufacturers - Specialty & Generic Industry

Max
125.42%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

NBIX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ALHC vs. NBIX: A comparison of their Payout Ratio against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Dividend at a Glance

SymbolALHCNBIX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio

ALHC

-28.99

Medical - Healthcare Plans Industry

Max
18.17
Q3
17.32
Median
15.48
Q1
13.55
Min
12.84

ALHC has a negative P/E Ratio of -28.99. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

NBIX

42.09

Drug Manufacturers - Specialty & Generic Industry

Max
40.89
Q3
28.12
Median
23.94
Q1
18.79
Min
7.76

At 42.09, NBIX’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Drug Manufacturers - Specialty & Generic industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

ALHC vs. NBIX: A comparison of their P/E Ratio against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Forward P/E to Growth Ratio

ALHC

-0.99

Medical - Healthcare Plans Industry

Max
1.41
Q3
1.09
Median
0.85
Q1
0.79
Min
0.60

ALHC has a negative Forward PEG Ratio of -0.99. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

NBIX

1.48

Drug Manufacturers - Specialty & Generic Industry

Max
4.19
Q3
2.94
Median
1.47
Q1
0.35
Min
0.00

NBIX’s Forward PEG Ratio of 1.48 is within the middle range of its peers in the Drug Manufacturers - Specialty & Generic industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.

ALHC vs. NBIX: A comparison of their Forward PEG Ratio against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Price-to-Sales Ratio

ALHC

0.89

Medical - Healthcare Plans Industry

Max
0.94
Q3
0.64
Median
0.43
Q1
0.27
Min
0.16

ALHC’s P/S Ratio of 0.89 is in the upper echelon for the Medical - Healthcare Plans industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

NBIX

5.30

Drug Manufacturers - Specialty & Generic Industry

Max
7.49
Q3
4.45
Median
2.12
Q1
1.21
Min
0.25

NBIX’s P/S Ratio of 5.30 is in the upper echelon for the Drug Manufacturers - Specialty & Generic industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

ALHC vs. NBIX: A comparison of their P/S Ratio against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Price-to-Book Ratio

ALHC

24.30

Medical - Healthcare Plans Industry

Max
4.08
Q3
3.83
Median
2.63
Q1
1.74
Min
0.96

At 24.30, ALHC’s P/B Ratio is at an extreme premium to the Medical - Healthcare Plans industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

NBIX

5.08

Drug Manufacturers - Specialty & Generic Industry

Max
4.93
Q3
3.95
Median
2.14
Q1
1.30
Min
0.13

The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - Specialty & Generic industry.

ALHC vs. NBIX: A comparison of their P/B Ratio against their respective Medical - Healthcare Plans and Drug Manufacturers - Specialty & Generic industry benchmarks.

Valuation at a Glance

SymbolALHCNBIX
Price-to-Earnings Ratio (P/E, TTM)-28.9942.09
Forward PEG Ratio (TTM)-0.991.48
Price-to-Sales Ratio (P/S, TTM)0.895.30
Price-to-Book Ratio (P/B, TTM)24.305.08
Price-to-Free Cash Flow Ratio (P/FCF, TTM)140.7525.96
EV-to-EBITDA (TTM)-55.8224.14
EV-to-Sales (TTM)0.755.40